Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase 2 coopERA BC study

Aditya Bardia1, Tharu M Fernando2, Peter A Fasching3, Vanessa Quiroga4, Yeon H Park5, Jennifer M Giltnane2, Cloris Xue6, Vanesa López-Valverde7, Jutta Steinseifer7, Pablo Diego Pérez-Moreno2, Heather M Moore2, Sara A Hurvitz8


BACKGROUND

- Two weeks of giredestrant treatment exhibited a marked ER degradation across multiple clinical subgroups (Figure 2).
- Baseline Ki67 scores were observed lower in tumors with higher-risk features: the higher Ki67 score, the residual residual positivity and PgR negativity (Figure 3). 
- Ki67 response was more variable in treatment-naive tumors, with no overlap of Ki67 percent changes at baseline and Ki67 percent changes at Week 2 from baseline (Figure 3).
- Baseline ER H-scores were found in a substantial proportion of tumors, baseline ER H-scores were observed lower in tumors with higher-risk features: the higher Ki67 score, the residual residual positivity and PgR negativity (Figure 4).

METHODS

- Patients with ER+/HER2– untreated BC (locally assessed cT1–cT4, cN0–cN2; ER+, HER2– untreated BC (locally assessed cT1c (≥ 1.5 cm)–cT4a–c ER+/HER2– eBC and baseline Ki67 score ≥50 have been included. CI, confidence interval; PgR, progesterone receptor.

RESULTS

- Ki67 responses were defined as ≤2.7%, intermediate as >2.7% and <7.4%, and sensitive as ≥7.4% (Table 2).
- Exploratory subgroup analysis revealed that 2 weeks of giredestrant treatment resulted in marked Ki67 reduction across multiple clinical subgroups including those with higher Ki67 scores at baseline.
- Ki67 score ≥50 have been included in C–D. Ana, anastrozole; BL, baseline; ER, oestrogen receptor; PgR, progesterone receptor.
- End of study treatment.
- Baseline was the patient’s last observation prior to initiation of study drug. Bars represent the mean relative reduction based on the relative change of ER and PgR H-scores at Week 2 compared to baseline (95% CI).

CONCLUSIONS

- Ki67 responses were defined as ≤2.7%, intermediate as >2.7% and <7.4%, and sensitive as ≥7.4%.
- Baseline ER H-scores were found to be predictive of Ki67 response in treatment-naive tumors.

REFERENCES


CONFLICTS OF INTEREST

A.R. declares potential conflicts of interest for Novartis, BMS, Genentech, Lilly, and Genentech/Novartis. A.R. and M.W. have provided consulting to Amgen, Sanofi. M.W. has received research support from Amgen, Sanofi. M.W. and A.R. have served as speakers for Amgen and Sanofi. A.A. has served as a consultant for Amgen and Sanofi. M.W. and A.R. have received grant support from Amgen, Sanofi. M.W. and A.R. have received honoraria from Amgen, Sanofi. M.W. and A.R. have received research support from Amgen, Sanofi. M.W. and A.R. have served as members of advisory panels for Amgen, Sanofi. M.W. and A.R. have served as speakers for Amgen and Sanofi.